Linda Engle is a prominent inventor based in Framingham, MA (US). She has made significant contributions to the field of biotechnology, holding a total of 16 patents. Her work focuses on developing innovative solutions for various medical conditions.

Latest Patents

One of her latest patents is for fibronectin-based scaffold domain proteins that bind to myostatin. This invention relates to the use of these proteins in therapeutic applications aimed at treating muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. Additionally, it encompasses cells comprising such proteins, polynucleotides encoding these proteins or fragments thereof, and vectors that include the polynucleotides. Another notable patent is for bispecific EGFR/IGFIR binding molecules. This invention involves bispecific molecules that contain an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research, and therapeutic applications. It also includes cells comprising such proteins, polynucleotides encoding these proteins or fragments thereof, and vectors that comprise the polynucleotides encoding these innovative proteins.

Career Highlights

Linda Engle is currently associated with Bristol-Myers Squibb Company, where she continues to advance her research and development efforts. Her work has been instrumental in creating new therapeutic options that address critical health issues.

Collaborations

Some of her notable coworkers include Ginger Chao Rakestraw and Sharon T. Cload. Their collaborative efforts contribute to the innovative environment at Bristol-Myers Squibb.

Conclusion

Linda Engle's contributions to biotechnology through her patents and collaborative work highlight her role as a leading inventor in the field. Her innovations have the potential to significantly impact the treatment of various medical conditions.

This text is generated by artificial intelligence and may not be accurate.